AstraZeneca Enhertu DESTINY-Lung04 Trial Demonstrates 14.3-Month Median PFS in First-Line HER2-Mutant NSCLC
Results from the AstraZeneca Enhertu DESTINY-Lung04 Trial show a 37% reduction in risk of disease progression or death, establishing first-line efficacy for T-DXd in HER2-mutant non-small cell lung cancer.
